Advaxis has dosed the first patient in a Phase l trial of ADXS-NEO for the treatment of metastatic non-small cell lung cancer (NSCLC), metastatic microsatellite stable colon cancer and metastatic squamous head and neck cancer.

The first patient dosed with ADXS-NEO is affected by non-small cell lung cancer.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The open-label, dose-escalation, multi-centre clinical trial is currently being conducted in the US.

As part of the trial, Advaxis will conduct a biopsy of the patients and then develop an investigational personalised treatment for each patient based on an analysis of their tumour neoantigen mutations, which will be ready to be dosed within eight weeks of the initial biopsy.

Around 48 subjects are expected to be enrolled in the trial, which is expected to be completed by September 2020.

“This programme brings our clinically validated Lm Technology to the cutting-edge area of neoantigen immuno-oncology.”

Advaxis president and CEO Kenneth Berlin said: “This programme brings our clinically validated Lm Technology to the cutting-edge area of neoantigen immuno-oncology.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“We are committed to realising the potential of ADXS-NEO to mobilise patients’ immune systems against mutations that accumulate within and contribute to the development of their cancer, and to bring the potential benefits of our technology to more patients and their families.”

ADXS-NEO is currently being investigated as a personalised Listeria monocytogenes (Lm)-based immunotherapy designed to produce an immune response against mutation-derived tumour-specific neoantigens identified through DNA sequencing of a patient’s own tumours.

Advaxis had previously partnered with Amgen in order to develop ADXS-NEO.